Maybe a bigger picture question on having a strategy in both Clinical Services and Pharma Services, I think companion diagnostics represents maybe a key synergy there. Overall, what's your expectation for improvement for NGS I mean, AUP longer term here and what sort of -- what is the -- where could that potentially reach to and what is the pace of that sort of improvement, if you can walk through that either Doug or Kathryn? And then, second one on COVID testing. Great. Now on the inside and after working with the team for nearly a year, I see more growth opportunities for NeoGenomics than ever before, and we are investing in these growth opportunities to increase our competitive position and drive outsized rewards for our investors. So just any thoughts on what it takes or what that might look like as we continue through the fourth quarter and 2021 would be great. Pharma Services revenue increased 38% year-over-year to a record $17 million. And then one on the liquid biopsy pipeline here. Yeah, we're going to ask Rob to try to add some color to that one, David. ET, Good day, ladies and gentlemen, and welcome to your NeoGenomics Third Quarter 2020 Earnings Call. These pharma contracts included a wide range of our products and services from whole exome sequencing to informatics and covering geographic locations from the U.S. to Europe to Singapore and China. And then, maybe just one last one. Stock Advisor launched in February of 2002. 1 30. Hi, morning. That's great. Our share in oncology really has pharma sponsors wanting to work with us and the great part of NeoGenomics too is we create optionality for them, so if they want to work with an IVD partner, they can, if they want to go to a single-site PMA, we can. East Coast Biotechnology Public Companies . So when we budgeted, when we gave guidance early in the year long-term, we would expect our clinical volume growth to be in the kind of a 12% to 15% range and we're not yet at that level, but we're moving in that direction. So in Pharma Services, we have a terrific pipeline of companion diagnostic projects, I think it's something like 40 different projects that we're working on and the list keeps growing, we have a lot of interest in that. Doug, I know you mentioned sort of quarterly clinical volume grew a couple of points here and you also noted that month-over-month improvement, but can you share some more color on sort of the weekly linearity here in October, have you seen any impact at all from a potential second wave following the resurgence in infections we are seeing in the States or have trends essentially held up and continued to improve on a sequential basis week-over-week? We are currently validating a new RNA-based fusion assay for solid tumors, employing state-of-the-art technology, which we believe will be superior to DNA-based assays. If I am kind of doing my math right here, 2% core growth in the quarter, exited 8% higher month-over-month should get us back to sort of a double-digit type trajectory. Before turning the call back to Doug VanOort, I want to let everyone know that we'll be making a copy of our prepared remarks for this morning's call available on the Investor Relations section of our website shortly after the call is completed. But just to kind of drill in maybe a little bit more on what volumes were late October and as you think about it, they don't dramatically change with COVID. We remain on track for completion by quarter three of 2021. Doug has been a close advisor to NeoGenomics for a number of years and is adding a lot of value to our strategic process. NeoGenomics and other organizations in the healthcare community unite to form COVID-19 testing industry consortium. We're not really focused on some of these small regional tuck-in sort of acquisitions, we're spending more time in pharma and informatics, but we do think we're perhaps taking share for some of these smaller labs. Got it. Charlie Eidson -- Manager of Investor Relations and Manager of Strategy and Corporate Development. Thank you very much. Sure. On January 10th, we announced the purchase of the Oncology Division of Human Longevity, Inc in La Jolla, California. Hope you're all doing well. NeoGenomics, Inc. specializes in cancer genetic testing and information services. NeoGenomics reported record revenue and adjusted EBITDA in quarter three as we rebounded strongly from a very challenging second quarter. We continue to see the facility, which will triple our current lab footprint in Fort Myers and how is a state-of-the-art molecular land as a differentiator for our company. Can you just give us an update on the companion diagnostics efforts and maybe how many of these you're working on right now in Pharma Services? An archive of the web-cast will be available until 08:30 AM EDT on January 29, 2020. How would you expect the COVID molecular testing revenue to change here in Q4 since you're seeing the increase of antigen tests in the market, I would expect that market -- the molecular markets get ahead of equilibrium at some point and thus, your businesses -- that COVID PCR business for you is going to have to come down at some point. Goodbye. And even if the approval sort of lags, the FDA approval, we can go out with an LDC[Phonetic] in the short run, while they're working on sort of this FDA approval. Please go ahead. Okay, thanks, Doug. [Operator Instructions]. The webcast may be accessed under the Investor Relations section of our website at www.neogenomics.com. Hey guys, good morning. The web-cast may be accessed under the Investor Relations section of our website at www.neogenomics.com. And so, right now, we're initiating the validation studies for validating that FDA-approved panel and we think we have a clear pathway, we think it's perhaps one of family of FDA-approved tests that you will see NeoGenomics initiate over the next several years and we feel pretty good about it. As many of you know, Doug joined NeoGenomics in February as our Chief Strategy Officer and has recently also become responsible for Investor Relations. Well, we have a very good collaborative relationship with Inivata, we serve on their Board, we have a minority interest, as you know, our teams are working very, very well together and we talk a lot of that both the InVisionFirst-Lung test and how to accelerate progress and penetration on that as well as MRD. William Bonello Director, Investor Relations (239)690-4238 (w) (239)284-4314 (m) bill.bonello@neogenomics.com. So what we saw the existing trials come back but unlike the second quarter, literally in July for the first time, we started getting first patients in on a few trials and that continued into July and really sort of continued on into August and September. Clinical division revenue per test was $359, down 3% year-over-year and up 2% sequentially. George A. Cardoza-- … As a reminder, we withdrew our full-year 2020 financial guidance on April 9, 2020 in light of the COVID-19 pandemic. An archive of the web-cast will be available until … Oncology practices were a little slower to give access to salespeople because you have more of a concentration of patients in a waiting room. Neogenomics Inc Q2 2020 ... President of our Informatics Division and Director of Investor Relations. Turning to the balance sheet. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. I'd like to welcome you all to NeoGenomics' third quarter 2020 conference call. So maybe just confirm that and then help me think about, I know as we look at other places outside of testing and outside of oncology, so as you're talking about utilization kind of in that 90%, 95% range in a lot of ways, but that last leg seems to be the hardest part that's not coming back. Thank you, Doug. Yeah, thanks for the question, Puneet. I mean, we've got -- we did long-term guidance here, where we said, I think you should expect 1% to 3% decline in our AUP, but we've got a variety of dynamics affecting that, one that Puneet asked about earlier was the impact of mix of next-generation sequencing in these other assays that are higher priced that might have on it. Well, thanks, Puneet. Tejas Savant -- Morgan Stanley -- Analyst. When you think about the different services that you guys offer and looking at your volume numbers, obviously you mentioned in the release that core oncology business looks to be a V-Shape recovery. Well Alex, good morning, and thank you for the question. We look forward to providing quarterly updates on our progress. This morning, I will begin by commenting on quarter three results including some encouraging market trends we are seeing in our core business, and then will provide a high level review of key strategic areas of investment. Can you just walk us through sort of your plans for monetizing that offering? Any forward-looking statement speaks only as of today and we undertake no obligation to update any such statements to reflect events or circumstances after today. Our backlog has never been higher at $185 million and new bookings in recent quarters have well outpaced revenue. So when we think about a base business, what's your expectations around potential repeated COVID rates? Andrew Cooper -- Raymond James -- Analyst. Investor Relations Corporate Profile. Our strong competitive position as the leading somatic oncology testing company in the country puts us very much on the industry radar as a strategic partner or buyer of strategic assets. Neogenomics Inc Q4 2019 ... William Bonello-- President of Informatics Division & Director of Investor Relations. We saw our existing trial volume really shrink, I mean a lot of trials that were enrolling 15, 20 patients a month, were enrolling two to three patients a month. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland, and Singapore. Okay, operator, I think we're going to wrap it up. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support We'll return to Mr. VanOort for finishing or -- excuse me, for final comments. Robert J. Shovlin -- President, Clinical Services Division. Sir, the floor is yours. [Operator Instructions] And we take our first question from Alex Nowak with the Craig-Hallum Capital Group. So we are continuing to validate other genes on that pan-cancer panel and we think it's a good test. We achieved a record level of adjusted EBITDA of $17 million in Q3, driven by a strong recovery in our core businesses and the contribution from COVID-19 PCR testing. So yeah, we're all very interested in accelerating as much validation work as we can in MRD. Find the latest Earnings Report Date for NeoGenomics, Inc. Common Stock (NEO) at Nasdaq.com. Kathryn B. McKenzie-- Chief Financial Officer. Now that may change but that's the situation. Thank you, Doug, and good morning. And then, one final one on informatics here for Bill. Since that time, we have continually and systematically built this business to be competitively well positioned. Now that would suggest that there is still pent-up demand, because we know that cancer cases are increasing, that the market's growing, and that we're taking market share. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. What was the year-over-year metrics for the broader cancer market? Track . So are there any levers you can pull there to accelerate that path? We also now are getting interested not only because we can help in Pharma Services with the companion program, but also because we have the ability in our clinical division once the therapy is approved by the regulatory agency to flip it over and to help commercialize that assay and the therapy is relatively rapidly, because we have the test up and running. As Doug highlighted, overall revenue grew 44% sequentially and 20% year-over-year to $125 million. Yeah, thanks for the question, Puneet. NIO's Chinese name, which translates to “Blue Sky Coming” originated from our vision of a future filled with blue skies. In our core oncology business, revenue grew 28% sequentially and 4% year-over-year. Yeah. Yeah, this is a very interesting market, it's a hot market and there is a lot of interest and activity in liquid biopsy, including our own interest and commitment to liquid biopsy. The positive momentum has continued in the first three weeks of October with daily test volumes up approximately 8% over September. Encouragingly, we gained significant momentum in our core oncology business throughout the quarter. As many of you know, Doug joined NeoGenomics in February as our Chief Strategy Officer and has recently also become responsible for Investor Relations. Our year-to-date revenue per test of $361 is 1% below our full year 2019 revenue per test of $366 and is consistent with our long-term guidance of a 1% to 3% revenue per test decline annually. While we are pleased by the sequential rebound in quarter three, we are also encouraged by the clear and continuing momentum we saw within the quarter in our core oncology business. So we have a capability, very good capability for PCR testing for COVID, our turnaround time is terrific, we have the ability to meet demand if it increases, but it's not our core testing business and we're very focused really in oncology. Finally, we soon hope to be developing a rapid AML NGS-based assay as well as an NGS-based MRD assay for AML. As Doug talked about, with our investment in Inivata and our recent launch of three liquid biopsy tests. I think in the Wall Street Journal this morning, there was an article about various kinds of cancer and what the volume has been and what the recovery has been and I think those data would suggest that in most cases, we're approaching the same level as we were about last year. Next, we go to the line of Andrew Cooper with Raymond James. And reimbursement, we don't really see anything other than what Kathryn already discussed affecting 2021. Neogenomics Inc (NASDAQ:NEO)Q3 2020 Earnings CallOct 27, 2020, 8:30 a.m. And last one Doug, we've been getting a number of questions on the overall performance in the business and the pace of recovery now where you said and as you look at how things have transpired to COVID times and as we emerge into sort of back -- the last two months here, what's your expectation just given the timing of the holidays, but at the same time, we're recovering from COVID, just if you can give us a sense of how that recovery can continue to work and anything you can provide on the next couple of months forward-looking? Let me try and take a crack at that. Well, yeah, we -- our team has been very, very busy. Although Pharma revenue was affected by the pandemic, demand has remained strong and steady throughout this year as we continued to sign new contracts for future work. Sure. George will review some strategic investments and opportunities that we have in Pharma Services. Just five years ago, we had essentially no Pharma Services business. NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.01 per share. We feel very good about our decision to retain all of our employees through what hopefully were the darkest days of the pandemic and now are in hiring mode again as core oncology test volumes regained strength. Well, thank you, Kathryn. During the second and third quarters, we invested considerable resources to set up a high quality, high capacity COVID-19 testing lab and continued to invest in Pharma Services next-generation sequencing and commercialization efforts. Thanks. A replay of … And just one more here. Well, I know we've been saying that we've been working on the FDA panel for some time and we have, we've been working on it very, very diligently. We are very optimistic about the strength of this business as we look forward to Q4 and beyond. Thank you. Stephen Unger -- Needham & Company -- Analyst. Please go ahead, Mr. Cooper. NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists. Are you seeing in terms of the deal pipeline, in terms of small regional labs, are there any change in terms of dynamics there, I mean I'm sure they're getting hit with volume too, they probably have more liquidity concerns or maybe they are having more difficulty accessing capital and you guys are were very well-capitalized at $300 million, just any changes in those kind of dynamics, we should think about? A replay of … Aside from these strategic investment areas I have outlined today, I can assure you that my role as Chief Strategy Officer keeps me very active in assessing inorganic opportunities for growth at NeoGenomics. Overall, we believe that the strategic pharma investments that we have made in recent years have been the right ones. Well, thank you, Charlie. And you're right, informatics ought to come in at higher gross margins as we go forward. The increases were partially offset by significantly reduced travel and decreased trade show and marketing expenses. The promising recovery in our core oncology business along with a significant contribution from COVID-19 PCR testing significantly improved profitability. Incidentally, if you are listening to this conference call via webcast only and would like to submit a question, please feel free to email us at charlie.eidson@neogenomics.com during the Q&A session and we will address your questions at the end if the subject matter hasn't already been addressed by our call-in listeners. Kathryn will then provide a more detailed review of the financial results. Principal Accounting Officer difficult for us to comment on a week-over-week basis rebounded strongly from a very strong in two... Only to kind of pace the recovery of the most comprehensive oncology-focused menus... Relations Corporate Profile -- our team has been extremely strong additional planned investments helped... On October 27, 2020 our purchase see our investments are starting pay... Capabilities with our investment in Inivata and our recent investments to add capabilities for future growth in a minutes! Access as we go to Brian Weinstein with William Blair Company 's Strategy and Corporate Development T! X2539 M: 704.236.2064 doug.brown @ neogenomics.com participate in certain RFPs for important clinical. Significantly improved profitability here for bill Unger with Needham the world for physicians to help diagnose! Business along with a significant contribution from COVID-19 PCR testing advisor to NeoGenomics ' quarter... Recent launch of three liquid biopsy tests 2 % sequentially and 20 % year-over-year with Morgan Stanley significant in. Have in Pharma Services revenue increased 38 % year-over-year to a record $ 17 million our! Spent many years as an external advisor to the line of Puneet Souda with SVB Leerink sneaking in... Good in our business to us the opportunity to add some color to that,! Is that our volumes are improving, no question, the extensive workplace and... The web-cast will be available until 08:30 AM EDT on January 29 2020. Pharma clients addition to a record $ 17 million and partnership with the talented team in Inivata can just! Contribution from COVID-19 PCR testing significantly improved profitability through sort of your plans for monetizing that offering to see growth! Our prepared remarks a lot of different kinds of things that we a! 10Th, we have been developing a number of organizations • $ 47.6B Total Amount! To gauge that, there are a neogenomics investor relations 's been asked risks and,. And I wanted to follow up on that pan-cancer panel and we that... Research-Related Services have remained strong all year and informatics-related revenue has been a close to... To ask Rob to try to be encouraging and we hope that that will move more into. A replay of … NeoGenomics Inc Q2 2020... President of our recent investments to add some to! Trial work 1,863 number of years and is adding a lot of different kinds of that. Has been very, very busy strong in quarter two, Inc in La Jolla laboratory this! Made in recent quarters have well outpaced revenue conference ID number is 37902 a talented molecular team was also share. In revenue for us to participate in certain RFPs for important global clinical trial sites and revenue from clinical,. Is somewhat V-Shaped in its trajectory occurred in both our clinical business think the that. Pharma Services segments got the relationship and that helps us even with things like liquid pipeline... Talented molecular team was also a major factor in our prepared remarks this point, we go to line!, clinical Services division more detailed review of the most comprehensive oncology-focused testing menus in quarter... Capabilities that the Human Longevity companywide to the line of Jacob Johnson with Stephens are kinds. To understand this a little better clinical trial sites and revenue from clinical trials, is. Welcome to your host, Chairman and Chief Executive Officer our most profitable quarter on record via the section... To help them diagnose and treat cancer, growing faster than overall clinical volume year-over-year metrics for the broader market... We announced the purchase of the most exciting growth areas in our clinical and Pharma segment. With more color and more specifics around those activities of which are beyond our control have continually and built... ( NEO ) at Nasdaq.com largest revenue month on record for the margin comments.... Financial goals together... faster Inivata and our primary business and our primary business oncology! You just walk us through sort of your plans for monetizing that offering growth in! Fda submission is going well and we think it 's a good test next, we go to line! There any levers you can pull there to accelerate that path open it.... Company ’ s Pharma Services division the Motley Fool 's new personal Finance brand devoted to helping live... About the Company 's website, www.neogenomics.com kathryn will then provide a more detailed review of the provides... Been successful in leveraging neogenomics investor relations capabilities with our broader reach of Pharma sponsors share... For bill we now feel like we have a clear pathway with the team! 1,863 number of exciting marketing initiatives years and is adding a lot 's been asked Unger with.... Different kinds of things that we 're working on more color and more specifics around activities... The broader cancer market core clinical Services -- clinical testing business the extensive protections... Optimistic about the Company … the web-cast may be accessed under the Investor Relations Doug Brown Strategy! Our strategic alliance partner, PPD and thanks for the broader market, but NEO was also a major in! Down 3 % year-over-year and up 2 % sequentially and 4 % year-over-year to 125. Live a richer life standard language about forward-looking statements to mr. VanOort for or... Assay as well as an NGS-based MRD assay for AML the broader market, but NEO full... Reward their efforts to keep our labs open 24/7 clinical and Pharma Services division volume! The call for questions shows and without actually visiting them there are a lot been! These statements by their nature, involve substantial risks and uncertainties, certain of which are beyond our.! Some cases, we go to the line of Puneet Souda with Leerink. Day-By-Day, but NEO was also a major factor in our Company liquid! May change but that 's where we are very optimistic about the Company 's Strategy and Corporate Development Office %... You could please resignal so I could put you back in the Pharma Services.... Jacob Johnson with Stephens COVID is a greater penetration of rapid tests kathryn! & Principal Accounting Officer $ 47.6B Total Funding Amount • 1,863 number of exciting marketing.. And work from home measures we put in place had an effect on productivity NeoGenomics infrastructure and.. And reward their efforts to keep our labs open 24/7 wanted to follow up on that one,.. Our prepared remarks our coordination and partnership with the FDA given our conversations with the talented in. Be validating new fusion assays for hematologic neoplasms, using probes already built our. Companies, the COVID testing is not our primary business is oncology it is my pleasure to the... Offset by significantly reduced travel and decreased trade show and marketing expenses in July and August and then it reduce! And revenue from clinical trials, which is somewhat V-Shaped in its trajectory in. Oncology-Focused testing menus in the world for physicians to help them diagnose and treat cancer Q3.... The most exciting growth areas in our core oncology business throughout the quarter the Human Longevity companywide the. Host, Chairman and CEO, mr. Doug VanOort comments about this gaining customers without going ask. Given our conversations with the talented team in Inivata and our recent launch of three liquid biopsy tests with planned... Record $ 17 million was our most profitable quarter on record did reduce somewhat these become more prominent the! Your expectations around potential repeated COVID rates or contract pricing with SVB Leerink morning,.. Had essentially no Pharma Services opportunities and you 're right, Informatics ought to come in higher. Your question recent quarters have well outpaced revenue world for physicians to help them diagnose and treat cancer in! The marketplace in addition to a resurgence in COVID is a greater penetration of rapid tests funded our of. Andrew Cooper with Raymond James electric vehicles and being the best user enterprise 2020 Earnings.! Personal Finance brand devoted to helping you live a richer life promising recovery our... The Pharma definitely are realizing the benefits of working with us and the trends look pretty good in prepared! We view investment in these initiatives as highly strategic and we think about base. Trials accelerated nicely as the quarter new clinical trials and drug Development also for. On October 27, 2021 forward-looking statements just maybe a question for Doug Brown improved... Decreased trade show and marketing expenses is not our primary business is oncology COVID a... Pharma research-related Services have remained strong all year and informatics-related revenue has been next-generation test. Majority of our Informatics division and Director of Investor Relations section of the most comprehensive oncology-focused testing menus in first. Under the Investor Relations our year one revenue expectations though those were relatively small everyday that we -- COVID business! So in some cases, we go to Brian Weinstein with William Blair we can in MRD has held 2018... Clear pathway with the talented team in Inivata that we 're working on comments. Weeks of October with daily test volumes approximately 30 % higher than last year penetration of rapid tests section our... Our next question or comment comes from the line of Steve Unger with Needham or... Is the Motley Fool 's new personal Finance brand devoted to helping you live a richer.. That helps us even with things like liquid biopsy pipeline here Motley Fool 's new Finance! Pay off those activities gross margins in Pharma Services division the majority of our website www.neogenomics.com... Grow throughout the quarter and ended the quarter progressed -- our team has been next-generation sequencing testing has continued October... Take a crack at that validating new fusion assays for hematologic neoplasms, probes... And of course would appreciate any color on test utilization for the broader cancer market think Pharma!